<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20100124003146N12</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2023-11-13</date_registration>
      <primary_sponsor>Kashan University of Medical Sciences</primary_sponsor>
      <public_title>The Effect of Flower Extract of Elaeagnus Angustifolia on Sexual Functioning in Menopausal Women</public_title>
      <acronym></acronym>
      <scientific_title>The Effect of Flower Extract of Elaeagnus Angustifolia on Sexual Functioning in Menopausal Women</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2023-11-21</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>68</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/72261</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Triple blinded, Placebo: Used, Assignment: Parallel, Purpose: Supportive, Randomization description: The samples will be randomly placed in two groups (test: A and control: B) based on the list prepared from the online randomization software and the address https://www.sealedenvelope.com/simple-randomiser/v1/lists . Random blocks of 4 will be selected, Blinding description: The first researcher, the research samples and the statistical analyst will not have any information about the names of the groups.</study_design>
      <phase>2</phase>
      <hc_freetext>sexual function.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: In this study, the hydroalcoholic extract of elderflower will be prepared in Asha Medicinal Herbs Trading Company, which will be purchased after the approval of the plan by the ethics committee and will be prepared in 1000 mg capsules and will be provided to the research units by a gynecologist. Intervention 2: Control group: Postmenopausal women who are randomly assigned to the control group will receive 1000 mg capsules containing corn starch (manufactured by Tardak Company (1 piece every 12 hours) for 35 days, which has no difference in appearance with elderflower extract.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
The results of the main outcome will be published.

When:
Access will start from the time the results are printed to forever.

To whom:
Academic and industrial researchers are allowed to submit data requests.

Conditions:
The applicant must first clearly state the purpose of the data request to the person in charge, and if approved by the university's research council, non-identifiable data will be provided to him.

Where to obtain:
Dr. Ismail Azizi Fini, email: azizifinies@yahoo.com

How to obtain:
After sending the request via email, it will be in the shortest time.

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Ismail Azizi Fini</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Kashan university of madical sciences</address>
        <city>Kashan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>8715981151</zip>
        <telephone>+98 36 1555 0021</telephone>
        <email>azizi-es@kaums.ac.ir</email>
        <affiliation>Kashan University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Ismail Azizi-Fini</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Ghotb Ravandi Blv- Pezashek Blv</address>
        <city>Kashan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>8715981151</zip>
        <telephone>+98 31 5554 0021</telephone>
        <email>azizi-es@kaums.ac.ir</email>
        <affiliation>Kashan University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>being married
Being Iranian
Getting a score of less than 28 on the questionnaire on women's sexual performance index
over 55 years old
Having regular sex with your spouse
Menopause diagnosed by a gynecologist
No history of uterine or breast cancer
Not being treated with chemotherapy or radiotherapy</inclusion_criteria>
      <agemin>50 years</agemin>
      <agemax>65 years</agemax>
      <gender>Female</gender>
      <exclusion_criteria>Unwillingness to participate in the study
Taking antidepressants or drugs related to sexual performance
having cognitive impairment based on the MMSE questionnaire (cutoff point 19)
Having a medical prohibition to have sex for the spouse, such as heart attacks or heart failure
A person suffering from chronic and active diseases that prevent sexual intercourse
Hormone therapy (estrogen, progesterone, testosterone) in the last month</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>E28.310</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Symptomatic premature menopause</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Placebo</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: In this study, the hydroalcoholic extract of elderflower will be prepared in Asha Medicinal Herbs Trading Company, which will be purchased after the approval of the plan by the ethics committee and will be prepared in 1000 mg capsules and will be provided to the research units by a gynecologist.</i_keyword>
      <i_keyword>Control group: Postmenopausal women who are randomly assigned to the control group will receive 1000 mg capsules containing corn starch (manufactured by Tardak Company (1 piece every 12 hours) for 35 days, which has no difference in appearance with elderflower extract.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>The sexual performance score of postmenopausal women is less than 28 from the FSFI questionnaire. Timepoint: At the beginning of the study (before the start of the intervention), the end of the intervention (35 days), one month after the end of the intervention. Method of measurement: Female Sexual Function Index.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Anxiety. Timepoint: At the beginning of the study (before the start of the intervention), the end of the intervention, one month after the end of the intervention. Method of measurement: Beck Anxiety Inventory.</sec_outcome>
      <sec_outcome>Sleep quality. Timepoint: At the beginning of the study (before the start of the intervention), the end of the intervention, one month after the end of the intervention. Method of measurement: Pittsburgh Sleep Quality Index.</sec_outcome>
      <sec_outcome>Number of times of intercourse per month. Timepoint: At the beginning of the study (before the start of the intervention), the end of the intervention, one month after the end of the intervention. Method of measurement: Questionnaire (one question about the number of sexual intercourses per month).</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Kashan University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2023-08-19</approval_date>
        <contact_name>Ethics committee of Kashan University of Medical Sciences</contact_name>
        <contact_address>5th Kilometer Qotb Ravandi Blouvar kashan Isfehan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
